12 Health Care Stocks Moving In Monday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
In Monday's pre-market session, several healthcare stocks experienced significant movements. Gainers included China SXT Pharmaceuticals (SXTC) with a 185.1% increase, cbdMD (YCBD) up by 62.04%, and Kintara Therapeutics (KTRA) rising by 48.91%. Aditxt (ADTX), Jin Medical International (ZJYL), and Elicio Therapeutics (ELTX) also saw notable gains. Conversely, Microbot Medical (MBOT), Cingulate (CING), Scinai Immunotherapeutics (SCNI), SenesTech (SNES), Fortress Biotech (FBIO), and Enveric Biosciences (ENVB) were among the losers, with declines ranging from 16.03% to 24.4%.
January 01, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kintara Therapeutics stock increased by 48.91% to $0.29.
KTRA's notable pre-market rise could attract more attention from investors, potentially leading to short-term upward momentum.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
China SXT Pharmaceuticals shares soared by 185.1% to $5.73, with a market cap of $3.2 million.
The substantial pre-market increase in SXTC's share price suggests a strong positive sentiment among investors, which could lead to further short-term gains.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
cbdMD stock increased by 62.04% to $1.28, with a market cap of $3.7 million.
The significant rise in YCBD's stock price indicates strong investor interest, which may continue to drive the stock up in the short term.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100
NEGATIVE IMPACT
Cingulate stock decreased by 24.04% to $7.46, with a market cap of $6.9 million.
The drop in CING's stock price could indicate a bearish outlook from investors, which may persist in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Microbot Medical stock fell 24.4% to $1.55, with a market cap of $18.1 million.
MBOT's significant pre-market drop could reflect negative investor sentiment, potentially leading to further short-term declines.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100
NEGATIVE IMPACT
Scinai Immunotherapeutics stock declined by 21.27% to $0.55, with a market cap of $2.3 million.
SCNI's pre-market decline suggests negative market sentiment, which could lead to further short-term price decreases.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 100